The expression of RCMTs, especially NSUN5, is generally upregulated in cancers
GEPIA2[8] (http://gepia2.cancer-pku.cn/#index) was used to explore the expression of RCMTs in cancers. As is shown in Table 1 and Fig. 1, the expression of RCMTs, except NSUN6 and NSUN7, is generally upregulated in cancers, compared to associated normal tissues respectively. In detail, NSUN1, NSUN2, NSUN3, NSUN4, NSUN5, NSUN6, NSUN7 and TRDMT1 were respectively upregulated in 23, 19, 18, 18, 25, 7, 12 and 13 types of cancers out of all the 31 types of cancers. Among them, the number of cancer types with upregulated NSUN5 was the most. (Table 1) NSUN5 was upregulated in ACC (Adrenocortical carcinoma), BLCA (Bladder Urothelial Carcinoma), BRCA (Breast invasive carcinoma), CESC (Cervical squamous cell carcinoma and endocervical adenocarcinoma), CHOL (Cholangiocarcinoma), COAD (Colon adenocarcinoma), DLBC (Lymphoid Neoplasm Diffuse Large B-cell Lymphoma), ESCA (Esophageal carcinoma), GBM (Glioblastoma multiforme), HNSC (Head and Neck squamous cell carcinoma ), KICH (Kidney Chromophobe), KIRP (Kidney renal papillary cell carcinoma ), LIHC (Liver hepatocellular carcinoma), LUAD (Lung adenocarcinoma), LUSC (Lung squamous cell carcinoma), OV (Ovarian serous cystadenocarcinoma), PAAD (Pancreatic adenocarcinoma), PRAD (Prostate adenocarcinoma), READ (Rectum adenocarcinoma), SKCM (Skin Cutaneous Melanoma), STAD (Stomach adenocarcinoma), TGCT (Testicular Germ Cell Tumors), THYM (Thymoma), UCEC (Uterine Corpus Endometrial Carcinoma) and UCS (Uterine Carcinosarcoma), downregulated in KIRC (Kidney renal clear cell carcinoma), LAML (Acute Myeloid Leukemia) and THCA (Thyroid carcinoma), and not significantly changed in LGG (Brain Lower Grade Glioma), PCPG (Pheochromocytoma and Paraganglioma) and SARC (Sarcoma). (Fig. 1) Therefore, we chose NSUN5 for further study.
Table 1
The expression of RCMTs in 31 types of cancers according to GEPIA2.
RCMTs
Cancers
|
NSUN1
|
NSUN2
|
NSUN3
|
NSUN4
|
NSUN5
|
NSUN6
|
NSUN7
|
TRDMT1
|
ACC
|
Down
|
NS
|
Down
|
Down
|
Up
|
Down
|
Down
|
Down
|
BLCA
|
Up
|
Up
|
NS
|
NS
|
Up
|
NS
|
NS
|
Down
|
BRCA
|
Up
|
Up
|
Up
|
Up
|
Up
|
Down
|
Up
|
Down
|
CESC
|
Up
|
NS
|
NS
|
NS
|
Up
|
Down
|
NS
|
Down
|
CHOL
|
Up
|
Up
|
Up
|
Up
|
Up
|
Down
|
Up
|
Up
|
COAD
|
Up
|
Up
|
Up
|
Up
|
Up
|
Up
|
Up
|
Up
|
DLBC
|
Up
|
Up
|
Up
|
Up
|
Up
|
Up
|
Down
|
Up
|
ESCA
|
Up
|
Up
|
Up
|
Up
|
Up
|
NS
|
NS
|
Up
|
GBM
|
Up
|
Up
|
Up
|
Up
|
Up
|
Down
|
Up
|
Up
|
HNSC
|
Up
|
Up
|
Up
|
Up
|
Up
|
Up
|
Down
|
NS
|
KICH
|
Down
|
Up
|
NS
|
Down
|
Up
|
Down
|
Up
|
Down
|
KIRC
|
Up
|
Up
|
NS
|
NS
|
Down
|
NS
|
Down
|
NS
|
KIRP
|
Up
|
Up
|
NS
|
Up
|
Up
|
Up
|
NS
|
NS
|
LAML
|
Up
|
Down
|
Up
|
Down
|
Down
|
Up
|
Up
|
Up
|
LGG
|
Up
|
Up
|
Up
|
Up
|
NS
|
Up
|
Up
|
Up
|
LIHC
|
Up
|
NS
|
Up
|
Up
|
Up
|
Down
|
NS
|
Up
|
LUAD
|
NS
|
Up
|
Up
|
Up
|
Up
|
Down
|
NS
|
Down
|
LUSC
|
Up
|
Up
|
Up
|
Up
|
Up
|
Down
|
Down
|
Down
|
OV
|
Up
|
Down
|
Up
|
Up
|
Up
|
Down
|
Up
|
Down
|
PAAD
|
Up
|
Up
|
Up
|
Up
|
Up
|
NS
|
Down
|
Up
|
PCPG
|
NS
|
NS
|
NS
|
Down
|
NS
|
NS
|
Down
|
NS
|
PRAD
|
Down
|
Down
|
NS
|
NS
|
Up
|
Down
|
Up
|
NS
|
READ
|
Up
|
Up
|
Up
|
Up
|
Up
|
NS
|
Up
|
Up
|
SARC
|
Up
|
Up
|
NS
|
NS
|
NS
|
NS
|
NS
|
NS
|
SKCM
|
Up
|
Down
|
Up
|
Up
|
Up
|
Down
|
Down
|
Up
|
STAD
|
Up
|
Up
|
Up
|
Up
|
Up
|
Down
|
Down
|
Up
|
TGCT
|
Up
|
NS
|
NS
|
Down
|
Up
|
Down
|
Down
|
Down
|
THCA
|
Down
|
Down
|
Down
|
Down
|
Down
|
Down
|
Down
|
Down
|
THYM
|
Up
|
Up
|
Up
|
Up
|
Up
|
Up
|
Down
|
Up
|
UCEC
|
NS
|
Down
|
Down
|
NS
|
Up
|
Down
|
Up
|
Down
|
UCS
|
NS
|
Down
|
Down
|
NS
|
Up
|
Down
|
Up
|
Down
|
Number of Cancer Types
(Up: NS: Down)
|
23:4:4
|
19:5:7
|
18:9:4
|
18:7:6
|
25:3:3
|
7:7:17
|
12:7:12
|
13:6:12
|
RCMTs, RNA m5C methyltransferases; NS, not significant. |
The hypomethylation of NSUN5 promoter may be responsible for its upregulation in cancers
To explore why NSUN5 was generally downregulated in cancers, we compared the methylation level of NSUN5 promoter in cancers and associated normal tissues using UALCAN[9] (http://ualcan.path.uab.edu/). Among the 28 types of cancers with DNA methylation data, the methylation level of NSUN5 promoter was downregulated in BRCA, HNSC, KIRC, LIHC, PAAD, STAD, TGCT, THCA and UCEC. Importantly, in BRCA, HNSC, LIHC, PAAD, STAD, TGCT and UCEC, the methylation level of NSUN5 promoter was downregulated, while the expression of NSUN5 was upregulated. Notably, the methylation level of NSUN5 promoter had a trend of downregulation in BLCA, CESC, ESCA, KIRP, LUAD, LUSC, PRAD, SARC, SKCM and THYM, although it was not significant. It may be due to the small quantity of normal tissues. (Fig. 2)
To sum up, the methylation level of NSUN5 promoter was generally downregulated in cancers, and may contribute to the upregulation of NSUN5, especially for BRCA, HNSC, LIHC, PAAD, STAD, TGCT and UCEC.
Higher expression of NSUN5 predicts poorer prognosis in multiple cancers
We then used GEPIA2 to explore whether the expression of NSUN5 in cancers was related with the prognosis of cancer patients. Among the 33 types of cancers (ACC, BLCA, BRCA, CESC, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KICH, KIRC, KIRP, LAML, LGG, LIHC, LUAD, LUSC, OV, PAAD, PCPG, PRAD, READ, SARC, SKCM, STAD, TGCT, THCA, THYM, UCEC, UCS and UVM (uveal melanoma)) with prognosis data in GEPIA2, higher expression of NSUN5 predicts lower OS (overall survival) for ACC (P = 0.0040), GBM (P = 0.0018), KIRC (P = 0.0079), LGG (P = 0.0060) and PRAD (P = 0.0330) patients, (Fig. 3)but predicts higher OS for SARC (P = 0.0420) and THYM (P = 0.0220) patients. (data not shown) The expression of NSUN5 was not associated with OS for the other 26 types of cancers. (P > 0.05) Furthermore, higher expression of NSUN5 predicts lower RFS (recurrence free survival) for ACC (P = 0.0140), LGG (P = 0.0140), LIHC (P = 0.0055), LUSC (P = 0.0500) and PRAD (P = 0.0180) patients. (Fig. 4) The expression of NSUN5 was not associated with RFS for the other 28 types of cancers. (P > 0.05)
Totally, higher expression of NSUN5 predicts poorer prognosis for ACC, LGG, PRAD (both for OS and RFS), GBM, KIRC (for OS), LIHC and LUSC (for RFS) patients.
Higher expression of NSUN5 was positively correlated with translation in cancers
To explore the function of NSUN5 in cancers, using LinkedOmics[10] (http://linkedomics.org/login.php), GO (gene ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses of NSUN5-correlated genes was performed in each cancer one by one. For example, in ACC, the co-expression analysis of NSUN5 (mRNA sequencing data) was shown in Supplementary Table 1 and Fig. 5A; the top 50 most significantly (according to FDR (false discovery rate)) NSUN5-positively-correlated and NSUN5-negatively-correlated genes were listed in Fig. 5B; the BPs (biological processes), CCs (cellular components), MFs (molecular functions) and KEGG pathways in which NSUN5-positively-correlated genes (FDR ≤ 0.05 and normalized enrichment score > 0) and NSUN5-negatively-correlated (FDR ≤ 0.05 and normalized enrichment score < 0) genes were significantly enriched were shown in Fig. 5C. The analyses process of the other 31 types of cancers were similar to that of ACC (data not shown).
The BPs, CCs, MFs and KEGG pathways in which NSUN5-positively correlated genes and NSUN5-negatively-correlated genes were significantly enriched in all the 32 types of human cancers were listed in Supplementary Tables 2–9.
To found the common BPs, CCs, MFs or KEGG pathways in human cancers, the number of cancer types with a same BP, CC, MF or KEGG pathway was calculated. The BPs, CCs, MFs or KEGG pathways were ranked by the times they appeared in cancers. The top 10 BPs, CCs, MFs and KEGG pathways in which NSUN5-positively-correlated genes were significantly enriched were listed in Tables 2–5, respectively. The top 10 BPs, CCs, MFs and KEGG pathways in which NSUN5-negatively-correlated genes were significantly enriched were listed in Supplementary Tables 10–13, respectively.
Table 2
The top 10 BPs in which NSUN5-positively-correlated genes were significantly enriched in cancers.
BP
Cancers
|
NADH dehydrogenase complex assembly
|
translational elongation
|
mitochondrial respiratory chain complex assembly
|
rRNA metabolic process
|
ncRNA processing
|
nucleoside monophosphate metabolic process
|
nucleoside triphosphate metabolic process
|
ribonucleoprotein complex biogenesis
|
translational initiation
|
tRNA metabolic process
|
ACC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
BLCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
BRCA
|
×
|
×
|
×
|
×
|
√
|
×
|
×
|
×
|
×
|
×
|
CESC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
CHOL
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
COADREAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
DLBC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
ESCA
|
√
|
√
|
×
|
×
|
×
|
√
|
√
|
×
|
√
|
√
|
GBM
|
√
|
√
|
√
|
×
|
×
|
√
|
√
|
×
|
×
|
√
|
HNSC
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
KICH
|
√
|
√
|
√
|
√
|
√
|
×
|
×
|
√
|
√
|
×
|
KIRC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
KIRP
|
√
|
√
|
√
|
√
|
√
|
×
|
×
|
√
|
×
|
×
|
LAML
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
LGG
|
√
|
×
|
√
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
LIHC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
LUAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
LUSC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
MESO
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
OV
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
PAAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
PCPG
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
PRAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
SARC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
SKCM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
STAD
|
√
|
√
|
√
|
√
|
×
|
×
|
×
|
√
|
√
|
√
|
TGCT
|
√
|
√
|
×
|
√
|
×
|
√
|
√
|
×
|
√
|
√
|
THCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
THYM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UCEC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UCS
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UVM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
Number of cancer types with “√”
|
30
|
29
|
28
|
27
|
26
|
26
|
26
|
26
|
25
|
24
|
BP analyses of NSUN5-correlated genes in cancers using Linkedomics. The BP in which NSUN5-positively-correlated genes were significantly enriched (FDR ≤ 0.05 and normalized enrichment score > 0) was denoted by “√”, otherwise, it was denoted by “×”. The BPs were ranked by the number of cancer types with “√” and only the top 10 BPs were shown. BP, biological process. |
A previous study showed that loss of the rRNA methyltransferase NSUN5 impairs global protein synthesis (translation) and normal growth.[11]Interestingly, in this study, we found that higher expression of NSUN5 in most cancers was positively correlated with translational elongation, rRNA metabolic process, ribonucleoprotein complex biogenesis, translational initiation, (Table 2) ribosome, (Tables 3 and 5) rRNA binding and unfolded protein binding, (Table 4) which were all associated with protein synthesis. For example, in ACC, higher expression of NSUN5 was positively correlated with translational elongation, rRNA metabolic process, ribonucleoprotein complex biogenesis, translational initiation and ribosome. (Table 6) The corresponding gene (mRNA) symbols were listed in Table 6.
Table 3
The top 10 CCs in which NSUN5-positively-correlated genes were significantly enriched in cancers.
CC
Cancers
|
mitochondrial inner membrane
|
mitochondrial membrane part
|
mitochondrial protein complex
|
NADH dehydrogenase complex
|
organelle envelope lumen
|
respiratory chain
|
ribosome
|
cytochrome complex
|
mitochondrial matrix
|
oxidoreductase complex
|
ACC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
BLCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
BRCA
|
√
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
CESC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
CHOL
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
COADREAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
DLBC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
ESCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
GBM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
√
|
HNSC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
KICH
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
KIRC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
KIRP
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
LAML
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
LGG
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
×
|
√
|
LIHC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
LUAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
LUSC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
MESO
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
OV
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
√
|
PAAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
PCPG
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
PRAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
SARC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
SKCM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
STAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
TGCT
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
THCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
THYM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UCEC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UCS
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UVM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
Number of cancer types with “√”
|
32
|
31
|
31
|
31
|
31
|
31
|
30
|
29
|
29
|
29
|
CC analyses of NSUN5-correlated genes in cancers using Linkedomics. The CC in which NSUN5-positively-correlated genes were significantly enriched (FDR ≤ 0.05 and normalized enrichment score > 0) was denoted by “√”, otherwise, it was denoted by “×”. The CCs were ranked by the number of cancer types with “√” and only the top 10 CCs were shown. CC, cellular component. |
Table 4
The top 10 MFs in which NSUN5-positively-correlated genes were significantly enriched in cancers.
MF
Cancers
|
oxidoreductase activity, acting on a heme group of donors
|
structural constituent of ribosome
|
electron transfer activity
|
oxidoreductase activity, acting on NAD(P)H
|
heme-copper terminal oxidase activity
|
rRNA binding
|
threonine-type peptidase activity
|
catalytic activity, acting on DNA
|
metal cluster binding
|
snRNA binding
|
unfolded protein binding
|
ACC
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
BLCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
BRCA
|
√
|
×
|
×
|
×
|
×
|
×
|
×
|
√
|
×
|
×
|
×
|
CESC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
CHOL
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
COADREAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
DLBC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
ESCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
GBM
|
√
|
√
|
√
|
√
|
×
|
×
|
√
|
×
|
×
|
×
|
√
|
HNSC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
KICH
|
×
|
√
|
×
|
×
|
×
|
√
|
√
|
×
|
×
|
×
|
×
|
KIRC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
KIRP
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
×
|
√
|
×
|
LAML
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
LGG
|
√
|
×
|
√
|
√
|
√
|
×
|
√
|
×
|
×
|
×
|
√
|
LIHC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
√
|
LUAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
LUSC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
MESO
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
OV
|
√
|
√
|
√
|
√
|
×
|
×
|
×
|
√
|
√
|
×
|
√
|
PAAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
PCPG
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
PRAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
SARC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
SKCM
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
×
|
√
|
√
|
×
|
STAD
|
√
|
√
|
√
|
×
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
TGCT
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
THCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
×
|
×
|
THYM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UCEC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UCS
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UVM
|
√
|
√
|
×
|
√
|
√
|
√
|
×
|
×
|
×
|
√
|
×
|
Number of cancer types with “√”
|
30
|
29
|
28
|
28
|
27
|
27
|
27
|
24
|
24
|
24
|
24
|
MF analyses of NSUN5-correlated genes in cancers using Linkedomics. The MF in which NSUN5-positively-correlated genes were significantly enriched (FDR ≤ 0.05 and normalized enrichment score > 0) was denoted by “√”, otherwise, it was denoted by “×”. The MFs were ranked by the number of cancer types with “√” and only the top 10 MFs were shown. MF, molecular function. |
Table 5
The top 10 pathways in which NSUN5-positively-correlated genes were significantly enriched in cancers.
Pathway
Cancers
|
Oxidative phosphorylation
|
Parkinson disease
|
Huntington disease
|
Non-alcoholic fatty liver disease (NAFLD)
|
Ribosome
|
Pyrimidine metabolism
|
Spliceosome
|
Alzheimer disease
|
Base excision repair
|
Proteasome
|
ACC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
×
|
BLCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
BRCA
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
×
|
CESC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
CHOL
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
COADREAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
DLBC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
ESCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
GBM
|
√
|
√
|
√
|
×
|
×
|
√
|
×
|
×
|
√
|
√
|
HNSC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
KICH
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
×
|
KIRC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
KIRP
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
×
|
√
|
√
|
LAML
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
√
|
×
|
LGG
|
√
|
√
|
×
|
√
|
×
|
×
|
×
|
√
|
×
|
√
|
LIHC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
LUAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
LUSC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
√
|
MESO
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
OV
|
√
|
√
|
√
|
×
|
√
|
√
|
√
|
√
|
×
|
√
|
PAAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
PCPG
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
PRAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
SARC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
SKCM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
STAD
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
√
|
TGCT
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
THCA
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
THYM
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UCEC
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UCS
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
√
|
UVM
|
√
|
√
|
√
|
√
|
√
|
×
|
√
|
√
|
√
|
×
|
Number of cancer types with “√”
|
31
|
31
|
30
|
29
|
29
|
28
|
28
|
27
|
26
|
26
|
KEGG pathway analyses of NSUN5-correlated genes in cancers using Linkedomics. The pathway in which NSUN5-positively-correlated genes were significantly enriched (FDR ≤ 0.05 and normalized enrichment score > 0) was denoted by “√”, otherwise, it was denoted by “×”. The pathways were ranked by the number of cancer types with “√” and only the top 10 pathways were shown. KEGG, Kyoto Encyclopedia of Genes and Genomes. |
Table 6
The translation-associated BPs, CCs, MFs and KEGG pathways in which NSUN5-positively correlated genes were significantly enriched in ACC.
Gene set
|
NES
|
FDR
|
Gene (mRNA) symbols
|
BP
|
translational elongation
|
1.708
|
0.026
|
AURKAIP1;EEF1A2;EEF1D;EEF2;EEF2K;EEFSEC;EIF5A;EIF5AL1;GADD45GIP1;
MRPL11;MRPL14;MRPL20;MRPL21;MRPL22;MRPL27;MRPL3;MRPL32;MRPL34;
MRPL36;MRPL4;MRPL41;MRPL42;MRPL47;MRPL51;MRPL52;MRPL54;MRPS11;
MRPS12;MRPS15;MRPS17;MRPS2;MRPS21;MRPS24;MRPS26;MRPS33;MRPS34;
MRPS36;PSTK;RPLP1;RPLP2;TUFM;ZNF598
|
BP
|
rRNA metabolic process
|
1.962
|
0.003
|
BRF1;BYSL;CD3EAP;DDX27;DDX49;DDX56;DEDD2;DHX37;DKC1;EBNA1BP2;
ERI3;ERN2;EXOSC1;EXOSC3;EXOSC5;FBL;FRG1;GAR1;GTF3A;GTF3C1;H2AFY;
ISG20;KRI1;KRR1;LAS1L;LYAR;MARS;MRPS11;MRTO4;NGDN;NHP2;NOB1;NOC4L;
NOL12;NOL6;NOL8;NOP10;NOP2;NOP56;NSA2;NSUN5;NVL;PA2G4;PIH1D1;POP4;
RIOK2;RPF2;RPL10A;RPL11;RPL26;RPL35;RPL35A;RPL5;RPL7A;RPS14;RPS15;RPS16;
RPS17;RPS19;RPS2;RPS21;RPS27;RPS28;RPS6;RPS7;RPS8;RPS9;RRP1;RRP9;RSL1D1;
SART1;SBDS;SMARCA4;SUV39H1;TBL3;UTP14A;UTP15;UTP20;WDR36;WDR46;ZNHIT3
|
BP
|
ribonucleoprotein complex biogenesis
|
2.039
|
0.001
|
ATXN2;ATXN2L;BCCIP;BRIX1;BYSL;CD2BP2;CELF5;CIRBP;DDX23;DDX27;DDX49;DDX56;
DENR;DHX37;DKC1;EBNA1BP2;EIF3B;EIF3CL;EIF3G;EIF3I;EIF3K;EIF3M;EIF4H;ERI3;EXOSC1;
EXOSC3;EXOSC5;FBL;FRG1;GAR1;GEMIN7;GNL2;GTF3A;GTPBP10;ISG20;KRI1;KRR1;LAS1L;
LSM14A;LSM4;LUC7L2;LYAR;MCTS1;MPV17L2;MRPL11;MRPL20;MRPL22;MRPS11;MRPS2;
MRTO4;MYBBP1A;NGDN;NHP2;NIP7;NOB1;NOC2L;NOC4L;NOL12;NOL6;NOL8;NOM1;NOP10;
NOP16;NOP2;NOP56;NPM1;NSA2;NSUN5;NVL;PA2G4;PIH1D1;POP4;PPAN;PPAN-P2RY11;PRMT7;
PRPF31;PRPF6;RAN;RBM22;RBMX;RIOK2;RPF2;RPL10;RPL10A;RPL11;RPL12;RPL13A;RPL24;RPL26;
RPL26L1;RPL35;RPL35A;RPL38;RPL5;RPL6;RPL7A;RPLP0;RPS10;RPS14;RPS15;RPS16;RPS17;RPS19;
RPS2;RPS21;RPS23;RPS27;RPS28;RPS5;RPS6;RPS7;RPS8;RPS9;RRP1;RRP9;RSL1D1;RSL24D1;
RUVBL2;SART1;SBDS;SF3A2;SNRPB;SNRPC;SNRPD2;SNRPD3;SNRPF;SNRPG;SRPK2;STRAP;
STYXL1;SURF6;SUV39H1;TAF9;TARBP2;TBL3;TRAF7;TXNL4A;UTP14A;UTP15;UTP20;WDR36;WDR46;XAB2;ZNF593;ZNHIT3
|
BP
|
translational initiation
|
2.207
|
0.000
|
ATF4;DENR;EIF1;EIF1AY;EIF2AK1;EIF2B1;EIF3B;EIF3CL;EIF3G;EIF3I;EIF3K;EIF3M;EIF4B;
EIF4E1B;EIF4EBP1;EIF4H;EIF6;HSPB1;LARP1;MCTS1;MTFMT;MTIF3;NPM1;PABPC1;PAIP1;
PAIP2;PPP1R15A;RPL10;RPL10A;RPL11;RPL12;RPL13;RPL13A;RPL14;RPL17;RPL18;RPL18A;
RPL21;RPL22;RPL24;RPL26;RPL28;RPL29;RPL3;RPL30;RPL31;RPL32;RPL34;RPL35;RPL35A;
RPL36;RPL36A;RPL37;RPL37A;RPL38;RPL39;RPL4;RPL41;RPL5;RPL6;RPL7A;RPL8;RPL9;RPLP0;
RPLP1;RPLP2;RPS10;RPS11;RPS13;RPS14;RPS15;RPS15A;RPS16;RPS17;RPS18;RPS19;RPS2;
RPS20;RPS21;RPS23;RPS24;RPS26;RPS27;RPS28;RPS29;RPS3;RPS4X;RPS4Y1;RPS5;RPS6;RPS7;
RPS8;RPS9;RPSA;RXRA;UBA52;YTHDF1
|
CC/MF
|
ribosome
|
2.306
|
0.000
|
APEX1;AURKAIP1;C12orf65;CHCHD1;DENR;EEF2;GADD45GIP1;HSPA14;LARP4;MCTS1;MPV17L2;
MRPL11;MRPL14;MRPL20;MRPL21;MRPL22;MRPL27;MRPL3;MRPL32;MRPL34;MRPL36;MRPL4;
MRPL41;MRPL42;MRPL47;MRPL51;MRPL52;MRPL54;MRPS11;MRPS12;MRPS15;MRPS17;MRPS2;
MRPS21;MRPS24;MRPS26;MRPS33;MRPS34;MRPS36;MT3;MTG1;NAA10;NDUFA7;NDUFAB1;RBM3;
RPL10;RPL10A;RPL11;RPL12;RPL13;RPL13A;RPL17;RPL18;RPL18A;RPL21;RPL24;RPL26;RPL26L1;
RPL28;RPL29;RPL3;RPL30;RPL31;RPL32;RPL34;RPL35;RPL35A;RPL36;RPL36AL;RPL37;RPL37A;
RPL38;RPL39;RPL4;RPL41;RPL5;RPL6;RPL7A;RPL8;RPL9;RPLP0;RPLP1;RPLP2;RPS10;RPS11;
RPS13;RPS14;RPS15;RPS15A;RPS16;RPS17;RPS18;RPS19;RPS2;RPS21;RPS23;RPS26;RPS27;
RPS28;RPS29;RPS3;RPS4X;RPS4Y1;RPS4Y2;RPS5;RPS6;RPS6KL1;RPS7;RPS8;RPS9;RRBP1;RSL24D1;SURF6;UBA52
|
KEGG
|
ribosome
|
2.620
|
0.000
|
FAU;MRPL11;MRPL14;MRPL20;MRPL21;MRPL22;MRPL27;MRPL3;MRPL32;MRPL34;MRPL36;
MRPL4;MRPS11;MRPS12;MRPS15;MRPS17;MRPS2;MRPS21;RPL10;RPL10A;RPL11;
RPL12;RPL13;RPL13A;RPL17;RPL18;RPL18A;RPL21;RPL24;RPL26;RPL26L1;RPL28;RPL29;
RPL3;RPL30;RPL31;RPL32;RPL34;RPL35;RPL35A;RPL36;RPL36AL;RPL37;RPL37A;RPL38;RPL39;
RPL4;RPL41;RPL5;RPL6;RPL7A;RPL8;RPL9;RPLP0;RPLP1;RPLP2;RPS10;RPS11;RPS13;RPS14;
RPS15;RPS15A;RPS16;RPS17;RPS18;RPS19;RPS2;RPS21;RPS23;RPS26;RPS27;RPS28;RPS29;
RPS3;RPS4X;RPS4Y1;RPS4Y2;RPS5;RPS6;RPS7;RPS8;RPS9;RSL24D1;UBA52
|
BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes; NES, normalized enrichment score; FDR, false discovery rate. |
In summary, higher expression of NSUN5 was positively correlated with translation-related mRNA, BPs, CCs, MFs and KEGG pathways in human cancers.